nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Losartan—type 2 diabetes mellitus	0.149	0.296	CbGbCtD
Naltrexone—ABCB1—Linagliptin—type 2 diabetes mellitus	0.098	0.195	CbGbCtD
Naltrexone—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0874	0.174	CbGbCtD
Naltrexone—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0632	0.126	CbGbCtD
Naltrexone—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0434	0.0863	CbGbCtD
Naltrexone—ABCB1—Glyburide—type 2 diabetes mellitus	0.0323	0.0643	CbGbCtD
Naltrexone—ABCB1—Losartan—type 2 diabetes mellitus	0.0296	0.0588	CbGbCtD
Naltrexone—Buprenorphine—CYP1A2—type 2 diabetes mellitus	0.000504	0.154	CrCbGaD
Naltrexone—Oxymorphone—CYP3A4—type 2 diabetes mellitus	0.000454	0.138	CrCbGaD
Naltrexone—Hydrocodone—CYP3A4—type 2 diabetes mellitus	0.000397	0.121	CrCbGaD
Naltrexone—Oxycodone—CYP3A4—type 2 diabetes mellitus	0.000362	0.11	CrCbGaD
Naltrexone—Buprenorphine—CYP3A4—type 2 diabetes mellitus	0.000334	0.102	CrCbGaD
Naltrexone—Naloxone—CYP3A4—type 2 diabetes mellitus	0.000331	0.101	CrCbGaD
Naltrexone—Hydromorphone—CYP3A4—type 2 diabetes mellitus	0.000329	0.1	CrCbGaD
Naltrexone—Naloxone—ALB—type 2 diabetes mellitus	0.000289	0.0881	CrCbGaD
Naltrexone—Morphine—CYP3A4—type 2 diabetes mellitus	0.00028	0.0853	CrCbGaD
Naltrexone—Oedema—Metformin—type 2 diabetes mellitus	0.000152	0.000401	CcSEcCtD
Naltrexone—Tinnitus—Ramipril—type 2 diabetes mellitus	0.000152	0.000401	CcSEcCtD
Naltrexone—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000152	0.0004	CcSEcCtD
Naltrexone—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000151	0.0004	CcSEcCtD
Naltrexone—Angioedema—Losartan—type 2 diabetes mellitus	0.000151	0.000399	CcSEcCtD
Naltrexone—Infection—Metformin—type 2 diabetes mellitus	0.000151	0.000398	CcSEcCtD
Naltrexone—Insomnia—Valsartan—type 2 diabetes mellitus	0.000151	0.000398	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.00015	0.000397	CcSEcCtD
Naltrexone—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.00015	0.000396	CcSEcCtD
Naltrexone—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.00015	0.000395	CcSEcCtD
Naltrexone—Chest pain—Irbesartan—type 2 diabetes mellitus	0.00015	0.000395	CcSEcCtD
Naltrexone—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.00015	0.000395	CcSEcCtD
Naltrexone—Myalgia—Irbesartan—type 2 diabetes mellitus	0.00015	0.000395	CcSEcCtD
Naltrexone—Shock—Metformin—type 2 diabetes mellitus	0.000149	0.000395	CcSEcCtD
Naltrexone—Insomnia—Orlistat—type 2 diabetes mellitus	0.000149	0.000394	CcSEcCtD
Naltrexone—Malaise—Losartan—type 2 diabetes mellitus	0.000149	0.000394	CcSEcCtD
Naltrexone—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000149	0.000393	CcSEcCtD
Naltrexone—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000149	0.000393	CcSEcCtD
Naltrexone—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000149	0.000393	CcSEcCtD
Naltrexone—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000149	0.000393	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000148	0.000392	CcSEcCtD
Naltrexone—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000148	0.000392	CcSEcCtD
Naltrexone—Somnolence—Valsartan—type 2 diabetes mellitus	0.000148	0.000392	CcSEcCtD
Naltrexone—Syncope—Losartan—type 2 diabetes mellitus	0.000148	0.000391	CcSEcCtD
Naltrexone—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000148	0.000391	CcSEcCtD
Naltrexone—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000148	0.00039	CcSEcCtD
Naltrexone—Skin disorder—Metformin—type 2 diabetes mellitus	0.000148	0.00039	CcSEcCtD
Naltrexone—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000147	0.000388	CcSEcCtD
Naltrexone—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000147	0.000388	CcSEcCtD
Naltrexone—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000147	0.000387	CcSEcCtD
Naltrexone—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000146	0.000386	CcSEcCtD
Naltrexone—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000146	0.000386	CcSEcCtD
Naltrexone—Palpitations—Losartan—type 2 diabetes mellitus	0.000146	0.000386	CcSEcCtD
Naltrexone—Nausea—Glimepiride—type 2 diabetes mellitus	0.000146	0.000385	CcSEcCtD
Naltrexone—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000145	0.000384	CcSEcCtD
Naltrexone—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000145	0.000383	CcSEcCtD
Naltrexone—Asthenia—Glyburide—type 2 diabetes mellitus	0.000145	0.000383	CcSEcCtD
Naltrexone—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000145	0.000383	CcSEcCtD
Naltrexone—Anorexia—Metformin—type 2 diabetes mellitus	0.000145	0.000382	CcSEcCtD
Naltrexone—Cough—Losartan—type 2 diabetes mellitus	0.000144	0.000381	CcSEcCtD
Naltrexone—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000144	0.000381	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000144	0.00038	CcSEcCtD
Naltrexone—Alopecia—Ramipril—type 2 diabetes mellitus	0.000144	0.00038	CcSEcCtD
Naltrexone—Fatigue—Valsartan—type 2 diabetes mellitus	0.000144	0.00038	CcSEcCtD
Naltrexone—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000144	0.000379	CcSEcCtD
Naltrexone—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000144	0.000379	CcSEcCtD
Naltrexone—Oedema—Irbesartan—type 2 diabetes mellitus	0.000143	0.000379	CcSEcCtD
Naltrexone—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000143	0.000379	CcSEcCtD
Naltrexone—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000143	0.000378	CcSEcCtD
Naltrexone—Pruritus—Glyburide—type 2 diabetes mellitus	0.000143	0.000378	CcSEcCtD
Naltrexone—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000143	0.000377	CcSEcCtD
Naltrexone—Constipation—Valsartan—type 2 diabetes mellitus	0.000143	0.000377	CcSEcCtD
Naltrexone—Infection—Irbesartan—type 2 diabetes mellitus	0.000142	0.000376	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000142	0.000376	CcSEcCtD
Naltrexone—Fatigue—Orlistat—type 2 diabetes mellitus	0.000142	0.000375	CcSEcCtD
Naltrexone—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000142	0.000374	CcSEcCtD
Naltrexone—Shock—Irbesartan—type 2 diabetes mellitus	0.000141	0.000372	CcSEcCtD
Naltrexone—Pain—Orlistat—type 2 diabetes mellitus	0.000141	0.000372	CcSEcCtD
Naltrexone—Arthralgia—Losartan—type 2 diabetes mellitus	0.000141	0.000372	CcSEcCtD
Naltrexone—Myalgia—Losartan—type 2 diabetes mellitus	0.000141	0.000372	CcSEcCtD
Naltrexone—Chest pain—Losartan—type 2 diabetes mellitus	0.000141	0.000372	CcSEcCtD
Naltrexone—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000141	0.000371	CcSEcCtD
Naltrexone—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000141	0.000371	CcSEcCtD
Naltrexone—Anxiety—Losartan—type 2 diabetes mellitus	0.00014	0.00037	CcSEcCtD
Naltrexone—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.00014	0.000369	CcSEcCtD
Naltrexone—Rash—Bromocriptine—type 2 diabetes mellitus	0.000139	0.000368	CcSEcCtD
Naltrexone—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000139	0.000368	CcSEcCtD
Naltrexone—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000139	0.000368	CcSEcCtD
Naltrexone—Tension—Ramipril—type 2 diabetes mellitus	0.000139	0.000367	CcSEcCtD
Naltrexone—Discomfort—Losartan—type 2 diabetes mellitus	0.000139	0.000367	CcSEcCtD
Naltrexone—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000139	0.000367	CcSEcCtD
Naltrexone—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000139	0.000366	CcSEcCtD
Naltrexone—Headache—Bromocriptine—type 2 diabetes mellitus	0.000139	0.000366	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000138	0.000365	CcSEcCtD
Naltrexone—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000138	0.000365	CcSEcCtD
Naltrexone—Nervousness—Ramipril—type 2 diabetes mellitus	0.000138	0.000364	CcSEcCtD
Naltrexone—Dry mouth—Losartan—type 2 diabetes mellitus	0.000138	0.000363	CcSEcCtD
Naltrexone—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000137	0.000361	CcSEcCtD
Naltrexone—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000136	0.00036	CcSEcCtD
Naltrexone—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000136	0.00036	CcSEcCtD
Naltrexone—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000136	0.00036	CcSEcCtD
Naltrexone—Confusional state—Losartan—type 2 diabetes mellitus	0.000136	0.000359	CcSEcCtD
Naltrexone—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000136	0.000359	CcSEcCtD
Naltrexone—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000135	0.000358	CcSEcCtD
Naltrexone—Somnolence—Metformin—type 2 diabetes mellitus	0.000135	0.000357	CcSEcCtD
Naltrexone—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000135	0.000356	CcSEcCtD
Naltrexone—Oedema—Losartan—type 2 diabetes mellitus	0.000135	0.000356	CcSEcCtD
Naltrexone—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000135	0.000356	CcSEcCtD
Naltrexone—Infection—Losartan—type 2 diabetes mellitus	0.000134	0.000354	CcSEcCtD
Naltrexone—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000134	0.000353	CcSEcCtD
Naltrexone—Tremor—Ramipril—type 2 diabetes mellitus	0.000133	0.000351	CcSEcCtD
Naltrexone—Shock—Losartan—type 2 diabetes mellitus	0.000133	0.00035	CcSEcCtD
Naltrexone—Urticaria—Valsartan—type 2 diabetes mellitus	0.000132	0.00035	CcSEcCtD
Naltrexone—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000132	0.000349	CcSEcCtD
Naltrexone—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000132	0.000349	CcSEcCtD
Naltrexone—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000132	0.000348	CcSEcCtD
Naltrexone—Tachycardia—Losartan—type 2 diabetes mellitus	0.000132	0.000348	CcSEcCtD
Naltrexone—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000131	0.000347	CcSEcCtD
Naltrexone—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000131	0.000347	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000131	0.000346	CcSEcCtD
Naltrexone—Fatigue—Metformin—type 2 diabetes mellitus	0.000131	0.000346	CcSEcCtD
Naltrexone—Urticaria—Orlistat—type 2 diabetes mellitus	0.000131	0.000346	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000131	0.000345	CcSEcCtD
Naltrexone—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.00013	0.000344	CcSEcCtD
Naltrexone—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.00013	0.000344	CcSEcCtD
Naltrexone—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.00013	0.000344	CcSEcCtD
Naltrexone—Asthenia—Gliclazide—type 2 diabetes mellitus	0.00013	0.000344	CcSEcCtD
Naltrexone—Agitation—Ramipril—type 2 diabetes mellitus	0.00013	0.000344	CcSEcCtD
Naltrexone—Constipation—Metformin—type 2 diabetes mellitus	0.00013	0.000343	CcSEcCtD
Naltrexone—Angioedema—Ramipril—type 2 diabetes mellitus	0.000129	0.000342	CcSEcCtD
Naltrexone—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000129	0.00034	CcSEcCtD
Naltrexone—Anorexia—Losartan—type 2 diabetes mellitus	0.000129	0.00034	CcSEcCtD
Naltrexone—Vomiting—Glyburide—type 2 diabetes mellitus	0.000129	0.000339	CcSEcCtD
Naltrexone—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000128	0.000339	CcSEcCtD
Naltrexone—Malaise—Ramipril—type 2 diabetes mellitus	0.000128	0.000338	CcSEcCtD
Naltrexone—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000128	0.000337	CcSEcCtD
Naltrexone—Rash—Glyburide—type 2 diabetes mellitus	0.000127	0.000337	CcSEcCtD
Naltrexone—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000127	0.000337	CcSEcCtD
Naltrexone—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000127	0.000336	CcSEcCtD
Naltrexone—Syncope—Ramipril—type 2 diabetes mellitus	0.000127	0.000336	CcSEcCtD
Naltrexone—Headache—Glyburide—type 2 diabetes mellitus	0.000127	0.000334	CcSEcCtD
Naltrexone—Palpitations—Ramipril—type 2 diabetes mellitus	0.000125	0.000331	CcSEcCtD
Naltrexone—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000125	0.000331	CcSEcCtD
Naltrexone—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000125	0.000329	CcSEcCtD
Naltrexone—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000125	0.000329	CcSEcCtD
Naltrexone—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000124	0.000328	CcSEcCtD
Naltrexone—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000124	0.000328	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000124	0.000327	CcSEcCtD
Naltrexone—Cough—Ramipril—type 2 diabetes mellitus	0.000124	0.000327	CcSEcCtD
Naltrexone—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000124	0.000326	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000123	0.000325	CcSEcCtD
Naltrexone—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000123	0.000325	CcSEcCtD
Naltrexone—Convulsion—Ramipril—type 2 diabetes mellitus	0.000123	0.000324	CcSEcCtD
Naltrexone—Constipation—Irbesartan—type 2 diabetes mellitus	0.000123	0.000324	CcSEcCtD
Naltrexone—Pain—Irbesartan—type 2 diabetes mellitus	0.000123	0.000324	CcSEcCtD
Naltrexone—Insomnia—Losartan—type 2 diabetes mellitus	0.000122	0.000322	CcSEcCtD
Naltrexone—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000121	0.000321	CcSEcCtD
Naltrexone—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000121	0.00032	CcSEcCtD
Naltrexone—Urticaria—Metformin—type 2 diabetes mellitus	0.000121	0.000319	CcSEcCtD
Naltrexone—Chest pain—Ramipril—type 2 diabetes mellitus	0.000121	0.000319	CcSEcCtD
Naltrexone—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000121	0.000319	CcSEcCtD
Naltrexone—Myalgia—Ramipril—type 2 diabetes mellitus	0.000121	0.000319	CcSEcCtD
Naltrexone—Dyspnoea—Losartan—type 2 diabetes mellitus	0.00012	0.000318	CcSEcCtD
Naltrexone—Anxiety—Ramipril—type 2 diabetes mellitus	0.00012	0.000318	CcSEcCtD
Naltrexone—Nausea—Glyburide—type 2 diabetes mellitus	0.00012	0.000317	CcSEcCtD
Naltrexone—Abdominal pain—Metformin—type 2 diabetes mellitus	0.00012	0.000317	CcSEcCtD
Naltrexone—Dizziness—Gliclazide—type 2 diabetes mellitus	0.00012	0.000317	CcSEcCtD
Naltrexone—Somnolence—Losartan—type 2 diabetes mellitus	0.00012	0.000317	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.00012	0.000316	CcSEcCtD
Naltrexone—Asthenia—Valsartan—type 2 diabetes mellitus	0.00012	0.000316	CcSEcCtD
Naltrexone—Discomfort—Ramipril—type 2 diabetes mellitus	0.000119	0.000315	CcSEcCtD
Naltrexone—Asthenia—Orlistat—type 2 diabetes mellitus	0.000118	0.000312	CcSEcCtD
Naltrexone—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000118	0.000312	CcSEcCtD
Naltrexone—Pruritus—Valsartan—type 2 diabetes mellitus	0.000118	0.000312	CcSEcCtD
Naltrexone—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000118	0.000312	CcSEcCtD
Naltrexone—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000117	0.00031	CcSEcCtD
Naltrexone—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000117	0.00031	CcSEcCtD
Naltrexone—Confusional state—Ramipril—type 2 diabetes mellitus	0.000117	0.000308	CcSEcCtD
Naltrexone—Pruritus—Orlistat—type 2 diabetes mellitus	0.000117	0.000308	CcSEcCtD
Naltrexone—Fatigue—Losartan—type 2 diabetes mellitus	0.000116	0.000307	CcSEcCtD
Naltrexone—Oedema—Ramipril—type 2 diabetes mellitus	0.000116	0.000305	CcSEcCtD
Naltrexone—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000116	0.000305	CcSEcCtD
Naltrexone—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000115	0.000305	CcSEcCtD
Naltrexone—Constipation—Losartan—type 2 diabetes mellitus	0.000115	0.000305	CcSEcCtD
Naltrexone—Pain—Losartan—type 2 diabetes mellitus	0.000115	0.000305	CcSEcCtD
Naltrexone—Rash—Gliclazide—type 2 diabetes mellitus	0.000114	0.000302	CcSEcCtD
Naltrexone—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000114	0.000302	CcSEcCtD
Naltrexone—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000114	0.000301	CcSEcCtD
Naltrexone—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000114	0.000301	CcSEcCtD
Naltrexone—Shock—Ramipril—type 2 diabetes mellitus	0.000114	0.000301	CcSEcCtD
Naltrexone—Headache—Gliclazide—type 2 diabetes mellitus	0.000114	0.0003	CcSEcCtD
Naltrexone—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000113	0.0003	CcSEcCtD
Naltrexone—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000113	0.000299	CcSEcCtD
Naltrexone—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000113	0.000299	CcSEcCtD
Naltrexone—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000113	0.000298	CcSEcCtD
Naltrexone—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000113	0.000298	CcSEcCtD
Naltrexone—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000112	0.000297	CcSEcCtD
Naltrexone—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000112	0.000295	CcSEcCtD
Naltrexone—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000111	0.000294	CcSEcCtD
Naltrexone—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.00011	0.000291	CcSEcCtD
Naltrexone—Dizziness—Valsartan—type 2 diabetes mellitus	0.00011	0.000291	CcSEcCtD
Naltrexone—Anorexia—Ramipril—type 2 diabetes mellitus	0.00011	0.000291	CcSEcCtD
Naltrexone—Dizziness—Orlistat—type 2 diabetes mellitus	0.000109	0.000288	CcSEcCtD
Naltrexone—Asthenia—Metformin—type 2 diabetes mellitus	0.000109	0.000288	CcSEcCtD
Naltrexone—Nausea—Gliclazide—type 2 diabetes mellitus	0.000108	0.000285	CcSEcCtD
Naltrexone—Pruritus—Metformin—type 2 diabetes mellitus	0.000107	0.000284	CcSEcCtD
Naltrexone—Urticaria—Losartan—type 2 diabetes mellitus	0.000107	0.000283	CcSEcCtD
Naltrexone—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000107	0.000282	CcSEcCtD
Naltrexone—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000107	0.000282	CcSEcCtD
Naltrexone—Vomiting—Valsartan—type 2 diabetes mellitus	0.000106	0.00028	CcSEcCtD
Naltrexone—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000106	0.000279	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000105	0.000278	CcSEcCtD
Naltrexone—Rash—Valsartan—type 2 diabetes mellitus	0.000105	0.000278	CcSEcCtD
Naltrexone—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000105	0.000277	CcSEcCtD
Naltrexone—Vomiting—Orlistat—type 2 diabetes mellitus	0.000105	0.000277	CcSEcCtD
Naltrexone—Insomnia—Ramipril—type 2 diabetes mellitus	0.000105	0.000276	CcSEcCtD
Naltrexone—Headache—Valsartan—type 2 diabetes mellitus	0.000104	0.000276	CcSEcCtD
Naltrexone—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000104	0.000274	CcSEcCtD
Naltrexone—Rash—Orlistat—type 2 diabetes mellitus	0.000104	0.000274	CcSEcCtD
Naltrexone—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000104	0.000274	CcSEcCtD
Naltrexone—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000104	0.000274	CcSEcCtD
Naltrexone—Headache—Orlistat—type 2 diabetes mellitus	0.000103	0.000273	CcSEcCtD
Naltrexone—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000103	0.000272	CcSEcCtD
Naltrexone—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000103	0.000272	CcSEcCtD
Naltrexone—Somnolence—Ramipril—type 2 diabetes mellitus	0.000103	0.000272	CcSEcCtD
Naltrexone—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000101	0.000268	CcSEcCtD
Naltrexone—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000101	0.000266	CcSEcCtD
Naltrexone—Dizziness—Metformin—type 2 diabetes mellitus	0.0001	0.000265	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	9.99e-05	0.000264	CcSEcCtD
Naltrexone—Fatigue—Ramipril—type 2 diabetes mellitus	9.97e-05	0.000263	CcSEcCtD
Naltrexone—Hypersensitivity—Losartan—type 2 diabetes mellitus	9.94e-05	0.000262	CcSEcCtD
Naltrexone—Nausea—Valsartan—type 2 diabetes mellitus	9.91e-05	0.000262	CcSEcCtD
Naltrexone—Constipation—Ramipril—type 2 diabetes mellitus	9.89e-05	0.000261	CcSEcCtD
Naltrexone—Diarrhoea—Irbesartan—type 2 diabetes mellitus	9.81e-05	0.000259	CcSEcCtD
Naltrexone—Nausea—Orlistat—type 2 diabetes mellitus	9.79e-05	0.000259	CcSEcCtD
Naltrexone—Asthenia—Losartan—type 2 diabetes mellitus	9.68e-05	0.000256	CcSEcCtD
Naltrexone—Vomiting—Metformin—type 2 diabetes mellitus	9.66e-05	0.000255	CcSEcCtD
Naltrexone—Rash—Metformin—type 2 diabetes mellitus	9.58e-05	0.000253	CcSEcCtD
Naltrexone—Dermatitis—Metformin—type 2 diabetes mellitus	9.57e-05	0.000253	CcSEcCtD
Naltrexone—Pruritus—Losartan—type 2 diabetes mellitus	9.54e-05	0.000252	CcSEcCtD
Naltrexone—Feeling abnormal—Ramipril—type 2 diabetes mellitus	9.53e-05	0.000252	CcSEcCtD
Naltrexone—Headache—Metformin—type 2 diabetes mellitus	9.52e-05	0.000251	CcSEcCtD
Naltrexone—Dizziness—Irbesartan—type 2 diabetes mellitus	9.48e-05	0.00025	CcSEcCtD
Naltrexone—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	9.46e-05	0.00025	CcSEcCtD
Naltrexone—Diarrhoea—Losartan—type 2 diabetes mellitus	9.23e-05	0.000244	CcSEcCtD
Naltrexone—Urticaria—Ramipril—type 2 diabetes mellitus	9.19e-05	0.000243	CcSEcCtD
Naltrexone—Abdominal pain—Ramipril—type 2 diabetes mellitus	9.14e-05	0.000241	CcSEcCtD
Naltrexone—Body temperature increased—Ramipril—type 2 diabetes mellitus	9.14e-05	0.000241	CcSEcCtD
Naltrexone—Vomiting—Irbesartan—type 2 diabetes mellitus	9.11e-05	0.000241	CcSEcCtD
Naltrexone—Rash—Irbesartan—type 2 diabetes mellitus	9.04e-05	0.000239	CcSEcCtD
Naltrexone—Dermatitis—Irbesartan—type 2 diabetes mellitus	9.03e-05	0.000238	CcSEcCtD
Naltrexone—Nausea—Metformin—type 2 diabetes mellitus	9.02e-05	0.000238	CcSEcCtD
Naltrexone—Headache—Irbesartan—type 2 diabetes mellitus	8.98e-05	0.000237	CcSEcCtD
Naltrexone—Dizziness—Losartan—type 2 diabetes mellitus	8.92e-05	0.000236	CcSEcCtD
Naltrexone—Vomiting—Losartan—type 2 diabetes mellitus	8.58e-05	0.000226	CcSEcCtD
Naltrexone—Hypersensitivity—Ramipril—type 2 diabetes mellitus	8.52e-05	0.000225	CcSEcCtD
Naltrexone—Nausea—Irbesartan—type 2 diabetes mellitus	8.51e-05	0.000225	CcSEcCtD
Naltrexone—Rash—Losartan—type 2 diabetes mellitus	8.51e-05	0.000225	CcSEcCtD
Naltrexone—Dermatitis—Losartan—type 2 diabetes mellitus	8.5e-05	0.000224	CcSEcCtD
Naltrexone—Headache—Losartan—type 2 diabetes mellitus	8.45e-05	0.000223	CcSEcCtD
Naltrexone—Asthenia—Ramipril—type 2 diabetes mellitus	8.3e-05	0.000219	CcSEcCtD
Naltrexone—Pruritus—Ramipril—type 2 diabetes mellitus	8.18e-05	0.000216	CcSEcCtD
Naltrexone—Nausea—Losartan—type 2 diabetes mellitus	8.01e-05	0.000212	CcSEcCtD
Naltrexone—Diarrhoea—Ramipril—type 2 diabetes mellitus	7.91e-05	0.000209	CcSEcCtD
Naltrexone—Dizziness—Ramipril—type 2 diabetes mellitus	7.65e-05	0.000202	CcSEcCtD
Naltrexone—Vomiting—Ramipril—type 2 diabetes mellitus	7.35e-05	0.000194	CcSEcCtD
Naltrexone—Rash—Ramipril—type 2 diabetes mellitus	7.29e-05	0.000193	CcSEcCtD
Naltrexone—Dermatitis—Ramipril—type 2 diabetes mellitus	7.29e-05	0.000192	CcSEcCtD
Naltrexone—Headache—Ramipril—type 2 diabetes mellitus	7.25e-05	0.000191	CcSEcCtD
Naltrexone—Nausea—Ramipril—type 2 diabetes mellitus	6.87e-05	0.000181	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.71e-05	0.000236	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.7e-05	0.000235	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AGT—type 2 diabetes mellitus	2.7e-05	0.000235	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.67e-05	0.000233	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	2.67e-05	0.000232	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	2.65e-05	0.000231	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CYBA—type 2 diabetes mellitus	2.65e-05	0.000231	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOB—type 2 diabetes mellitus	2.63e-05	0.000229	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.63e-05	0.000229	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—COX2—type 2 diabetes mellitus	2.63e-05	0.000229	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC5A2—type 2 diabetes mellitus	2.63e-05	0.000229	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.62e-05	0.000228	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—type 2 diabetes mellitus	2.61e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	2.61e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GHRL—type 2 diabetes mellitus	2.6e-05	0.000226	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLAT—type 2 diabetes mellitus	2.6e-05	0.000226	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.59e-05	0.000226	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.58e-05	0.000225	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.58e-05	0.000225	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA6—type 2 diabetes mellitus	2.58e-05	0.000224	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CALCA—type 2 diabetes mellitus	2.57e-05	0.000223	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—type 2 diabetes mellitus	2.54e-05	0.000221	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—UCP2—type 2 diabetes mellitus	2.54e-05	0.000221	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HSD11B1—type 2 diabetes mellitus	2.54e-05	0.000221	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—UCP3—type 2 diabetes mellitus	2.54e-05	0.000221	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LPL—type 2 diabetes mellitus	2.52e-05	0.000219	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GNB3—type 2 diabetes mellitus	2.5e-05	0.000218	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.5e-05	0.000218	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	2.49e-05	0.000217	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMOX1—type 2 diabetes mellitus	2.49e-05	0.000217	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.46e-05	0.000214	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAT—type 2 diabetes mellitus	2.46e-05	0.000214	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	2.45e-05	0.000213	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.45e-05	0.000213	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	2.44e-05	0.000212	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.42e-05	0.000211	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	2.42e-05	0.00021	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	2.42e-05	0.00021	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	2.41e-05	0.000209	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AVP—type 2 diabetes mellitus	2.39e-05	0.000208	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.39e-05	0.000208	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOB—type 2 diabetes mellitus	2.39e-05	0.000208	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PCK1—type 2 diabetes mellitus	2.39e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.38e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	2.38e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	2.38e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2.37e-05	0.000206	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.36e-05	0.000205	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	2.34e-05	0.000204	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	2.34e-05	0.000203	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	2.34e-05	0.000203	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—type 2 diabetes mellitus	2.34e-05	0.000203	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	2.33e-05	0.000203	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—type 2 diabetes mellitus	2.32e-05	0.000202	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.32e-05	0.000202	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOB—type 2 diabetes mellitus	2.31e-05	0.000201	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	2.3e-05	0.0002	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—type 2 diabetes mellitus	2.29e-05	0.000199	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—LPL—type 2 diabetes mellitus	2.28e-05	0.000198	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.27e-05	0.000198	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—C3—type 2 diabetes mellitus	2.26e-05	0.000197	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HK1—type 2 diabetes mellitus	2.23e-05	0.000194	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ADCY5—type 2 diabetes mellitus	2.23e-05	0.000194	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX1—type 2 diabetes mellitus	2.22e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.22e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LPL—type 2 diabetes mellitus	2.21e-05	0.000192	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	2.19e-05	0.00019	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2.18e-05	0.00019	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2.18e-05	0.00019	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—type 2 diabetes mellitus	2.18e-05	0.00019	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CD36—type 2 diabetes mellitus	2.17e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.16e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.16e-05	0.000188	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—KCNJ11—type 2 diabetes mellitus	2.16e-05	0.000188	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPA—type 2 diabetes mellitus	2.16e-05	0.000188	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GCKR—type 2 diabetes mellitus	2.16e-05	0.000188	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HSD3B2—type 2 diabetes mellitus	2.16e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.15e-05	0.000187	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGT—type 2 diabetes mellitus	2.15e-05	0.000187	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.14e-05	0.000186	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.12e-05	0.000184	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LEP—type 2 diabetes mellitus	2.11e-05	0.000183	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOE—type 2 diabetes mellitus	2.11e-05	0.000183	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.08e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.07e-05	0.00018	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDOB—type 2 diabetes mellitus	2.07e-05	0.00018	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	2.07e-05	0.00018	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—type 2 diabetes mellitus	2.05e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	2.05e-05	0.000178	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.03e-05	0.000177	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	2.02e-05	0.000176	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	2.02e-05	0.000176	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARA—type 2 diabetes mellitus	2.01e-05	0.000175	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	2.01e-05	0.000175	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	2e-05	0.000174	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.99e-05	0.000173	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—C3—type 2 diabetes mellitus	1.99e-05	0.000173	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.98e-05	0.000172	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	1.97e-05	0.000172	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	1.95e-05	0.00017	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AGT—type 2 diabetes mellitus	1.95e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.94e-05	0.000169	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GLP1R—type 2 diabetes mellitus	1.92e-05	0.000167	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.92e-05	0.000167	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CALM1—type 2 diabetes mellitus	1.92e-05	0.000167	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOE—type 2 diabetes mellitus	1.91e-05	0.000166	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.89e-05	0.000165	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.89e-05	0.000164	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOA1—type 2 diabetes mellitus	1.89e-05	0.000164	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.89e-05	0.000164	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.88e-05	0.000164	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	1.86e-05	0.000162	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.86e-05	0.000161	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	1.85e-05	0.000161	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.85e-05	0.000161	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.85e-05	0.000161	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.83e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.82e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—INS—type 2 diabetes mellitus	1.8e-05	0.000157	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	1.8e-05	0.000156	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.77e-05	0.000154	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	1.76e-05	0.000153	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	1.76e-05	0.000153	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.75e-05	0.000152	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.74e-05	0.000152	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.74e-05	0.000152	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.74e-05	0.000151	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.73e-05	0.000151	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	1.72e-05	0.00015	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.72e-05	0.000149	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	1.71e-05	0.000149	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	1.71e-05	0.000149	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	1.71e-05	0.000149	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	1.7e-05	0.000148	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—C3—type 2 diabetes mellitus	1.68e-05	0.000146	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	1.67e-05	0.000146	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—type 2 diabetes mellitus	1.66e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.65e-05	0.000144	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	1.65e-05	0.000144	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.65e-05	0.000143	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—INS—type 2 diabetes mellitus	1.63e-05	0.000142	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	1.62e-05	0.000141	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.6e-05	0.000139	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.6e-05	0.000139	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.59e-05	0.000139	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.58e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.58e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—INS—type 2 diabetes mellitus	1.58e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.57e-05	0.000136	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.56e-05	0.000136	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.56e-05	0.000136	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.55e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.54e-05	0.000134	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	1.54e-05	0.000134	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	1.54e-05	0.000134	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	1.54e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.53e-05	0.000133	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.53e-05	0.000133	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.52e-05	0.000132	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	1.51e-05	0.000131	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—type 2 diabetes mellitus	1.5e-05	0.00013	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	1.5e-05	0.00013	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.49e-05	0.000129	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.47e-05	0.000128	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.47e-05	0.000128	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	1.46e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.45e-05	0.000126	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—type 2 diabetes mellitus	1.43e-05	0.000125	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.43e-05	0.000125	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	1.41e-05	0.000122	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.39e-05	0.000121	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	1.39e-05	0.000121	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	1.39e-05	0.000121	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.39e-05	0.00012	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.39e-05	0.00012	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	1.36e-05	0.000118	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.35e-05	0.000118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.34e-05	0.000117	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—INS—type 2 diabetes mellitus	1.33e-05	0.000116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	1.33e-05	0.000116	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	1.33e-05	0.000116	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.33e-05	0.000116	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.31e-05	0.000114	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—type 2 diabetes mellitus	1.31e-05	0.000114	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.3e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.29e-05	0.000112	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.29e-05	0.000112	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.28e-05	0.000112	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.27e-05	0.00011	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.25e-05	0.000109	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.23e-05	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.23e-05	0.000107	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.19e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.18e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.17e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.17e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.17e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.17e-05	0.000102	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.15e-05	9.99e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.15e-05	9.99e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.14e-05	9.95e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.14e-05	9.9e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.13e-05	9.81e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.11e-05	9.67e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.1e-05	9.58e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.1e-05	9.56e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.1e-05	9.53e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.08e-05	9.38e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.07e-05	9.27e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.05e-05	9.1e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.04e-05	9.09e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.02e-05	8.91e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.02e-05	8.91e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.02e-05	8.91e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.02e-05	8.88e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1e-05	8.73e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.98e-06	8.68e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.94e-06	8.64e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	9.94e-06	8.64e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.87e-06	8.59e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	9.81e-06	8.54e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	9.42e-06	8.19e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.39e-06	8.17e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.29e-06	8.08e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	9.24e-06	8.04e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.16e-06	7.97e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.11e-06	7.92e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.98e-06	7.81e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	8.95e-06	7.78e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	8.8e-06	7.65e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	8.77e-06	7.63e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	8.67e-06	7.54e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	8.66e-06	7.53e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.43e-06	7.34e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	7.87e-06	6.85e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.74e-06	6.73e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	7.64e-06	6.64e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.59e-06	6.6e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—INS—type 2 diabetes mellitus	7.49e-06	6.51e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.26e-06	6.32e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.9e-06	6e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	6.87e-06	5.97e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—type 2 diabetes mellitus	6.58e-06	5.72e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	6.57e-06	5.71e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	6.57e-06	5.71e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.37e-06	5.54e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	6.01e-06	5.22e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.83e-06	5.07e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.38e-06	4.68e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	3.02e-06	2.63e-05	CbGpPWpGaD
